Patient characteristics
. | Microarray series by disease phenotype; n = 19 . | . | All patients by disease phenotype; n = 68 . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| Clinical characteristics . | Aggressive; n = 10 . | Indolent; n = 9 . | Aggressive; n = 18 . | Intermediate; n = 27 . | Indolent; n = 23 . | |||
| Male/female | 7/3 | 3/6 | 15/3 | 17/10 | 12/11 | |||
| Age, y, median (range) | 42.1 (22.3-55.9) | 49.3 (34.8-61.0) | 44.1 (20.6-56.0) | 48.7 (27.5-68.3) | 39.8 (20.8-64.1) | |||
| WBC count at diagnosis, × 109/L, median (range) | 234.0 (45.7-361.0) | 209.0 (82.8-336.0) | 202.4 (45.7-393.0) | 152.3 (16.1-506.0) | 149.0 (25.9-379.0) | |||
| Sokal score, median (range) | 0.89 (0.55-2.44) | 0.94 (0.64-3.90) | 0.92 (0.5-2.4) | 1.09 (0.5-1.9) | 1.0 (0.5-3.9) | |||
| Treatment prior to BT* | ||||||||
| BU | 2 | 1 | 5 | 0 | 4 | |||
| IFN | 5 | 3 | 7 | 20 | 16 | |||
| HU | 9 | 4 | 14 | 7 | 8 | |||
| Imatinib | 0 | 2 | 2 | 19 | 11 | |||
| Autograft | 0 | 1 | 0 | 0 | 6 | |||
| Allograft | 2 | 0 | 3 | 0 | 0 | |||
| Unknown | 0 | 4 | 0 | 2 | 4 | |||
. | Microarray series by disease phenotype; n = 19 . | . | All patients by disease phenotype; n = 68 . | . | . | |||
|---|---|---|---|---|---|---|---|---|
| Clinical characteristics . | Aggressive; n = 10 . | Indolent; n = 9 . | Aggressive; n = 18 . | Intermediate; n = 27 . | Indolent; n = 23 . | |||
| Male/female | 7/3 | 3/6 | 15/3 | 17/10 | 12/11 | |||
| Age, y, median (range) | 42.1 (22.3-55.9) | 49.3 (34.8-61.0) | 44.1 (20.6-56.0) | 48.7 (27.5-68.3) | 39.8 (20.8-64.1) | |||
| WBC count at diagnosis, × 109/L, median (range) | 234.0 (45.7-361.0) | 209.0 (82.8-336.0) | 202.4 (45.7-393.0) | 152.3 (16.1-506.0) | 149.0 (25.9-379.0) | |||
| Sokal score, median (range) | 0.89 (0.55-2.44) | 0.94 (0.64-3.90) | 0.92 (0.5-2.4) | 1.09 (0.5-1.9) | 1.0 (0.5-3.9) | |||
| Treatment prior to BT* | ||||||||
| BU | 2 | 1 | 5 | 0 | 4 | |||
| IFN | 5 | 3 | 7 | 20 | 16 | |||
| HU | 9 | 4 | 14 | 7 | 8 | |||
| Imatinib | 0 | 2 | 2 | 19 | 11 | |||
| Autograft | 0 | 1 | 0 | 0 | 6 | |||
| Allograft | 2 | 0 | 3 | 0 | 0 | |||
| Unknown | 0 | 4 | 0 | 2 | 4 | |||
WBC indicates white blood cell; BU, busulfan; IFN, interferon-α; HU, hydroxyurea; Autograft, autologous SCT; Allograft, allogeneic SCT; Unknown, not available because medical case records were irretrievable but most likely HU with or without IFN.
Main treatment during CP shown; most patients had more than one type of treatment over the course of their disease